Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year

Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period ended December 31, 2024. The company reported revenues of JPY 3.53 trillion ($22.4 billion), representing a 4.5% growth at constant exchange rates (CER). Sales jumped 14.6% year-on-year (YOY) due to the growth period and continuous progress in newly launched products. Third-quarter revenue was JPY 1.44 trillion, up 3.4% YOY.

Business Segment Performance

  • Gastrointestinal Diseases (GI): The GI segment had the highest revenue, with JPY 1.04 trillion during the reporting period, up 11% YOY. The main driver was Entyvio (Vedolizumab), which generated sales of JPY 699 billion (+12.9%).
  • Rare Diseases: Revenue was JPY 579 billion, up 10.4% YOY, with Takhzyro (lanadelumab) sales reaching JPY 68 billion (+23.2%).
  • Plasma Derived Therapy (PDT): Revenue was JPY 784.2 billion, up 16.3% YOY, driven by Immunoglobulin, which brought in JPY 576 billion in sales (+18.6%).
  • Oncology: Revenue was JPY 428.4 billion, up 23.7% YOY.
  • Neurological Diseases: Revenue was JPY 456.5 billion, down 3.9% YOY.
  • Vaccines: Revenue was JPY 49.9 billion, up 69.1% YOY.
  • Other Income: Including Azilsartan Azilva (Azilsartan) and Fosrenol (lanthanum carbonate), amounted to JPY 190.9 billion, down 16.1% YOY.

Geographic Revenue Distribution

  • US Market: JPY 1.84 trillion, accounting for 52.2% of total revenue.
  • European and Canadian Markets: 22.5% revenue share.
  • Growth and Emerging Markets: 16.1% revenue share.
  • Japanese Market: 9.2% revenue share.

Future Outlook and Pipeline
Takeda continues to advance multiple late-stage projects and is expected to complete three Phase III read-outs by 2025 (calendar year). The company plans to submit three regulatory applications between fiscal years 2025 and 2026, and five additional regulatory applications between fiscal years 2027 and 2029. Six of the late-stage projects are expected to achieve peak revenue of $10 billion to $20 billion, contributing to long-term growth. Takeda has raised its full-year (fiscal year 2024) revenue forecast from JPY 4.48 trillion to JPY 4.59 trillion.-Fineline Info & Tech

Leave a Reply

Your email address will not be published. Required fields are marked *

Insight, China's Pharmaceutical Industry